CoLucid Pharmaceuticals Relocates To Cambridge, Massachusetts, Region
03/24/2015
"We are very proud to have been a North Carolina-based company since our inception. However, given the expansion of our management team with Massachusetts-based executives, we feel it is the right time to relocate. Cambridge is the heart of the biotechnology industry and we are very excited to be a part of all the innovation and excitement that takes place here every day," said Thomas P. Mathers, CEO of CoLucid.
"We are thrilled to welcome CoLucid Pharmaceuticals to the Massachusetts life sciences community," said Robert K. Coughlin, President/CEO of MassBio, the Massachusetts life sciences trade association. "We know CoLucid will thrive in the ecosystem of innovation and collaboration here in the Commonwealth as they work to advance treatments for CNS disorders."
Project Announcements
Bosch Expands Lincolnton, North Carolina, Operations
06/02/2023
Little Leaf Farms Establishes McAdoo, Pennsylvania, Greens Production Complex
06/02/2023
Swiss-Based Sulzer Pumps Solutions Plans Easley, South Carolina, Operations
06/01/2023
Finland-Based ADMARES Plans Waycross, Georgia, U.S. Manufacturing Plant
06/01/2023
Toyota Plans Georgetown, Kentucky, Electric Vehicle Operations
06/01/2023
Ranger Design Establishes North Charleston, South Carolina, Operations
05/31/2023
Most Read
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
Is a Flurry of Fads Shaping Economic Development Policy?
Q2 2023
-
Nearshoring — North America’s Next Factory
Q2 2023
-
Front Line: Water Supply Increasingly Affecting Location Decisions
Q2 2023
-
Life Science Conversions in Real Estate
Q2 2023
-
First Person: Labor Crunch in the Construction Industry
Q2 2023
-
Companies Are Recalibrating Their Priorities
Q1 2023